Paolo C.
- Country
- Italy
- Department
- SC Ematologia - Dipartimento di Oncologia Medica ed Ematologia
Research Overview
- Phase I-II Study of Romidepsin Combined with CHOEP for Initial Treatment in Young Patients with Nodal Peripheral T-Cell Lymphomas Prior to Hematopoietic Stem Cell Transplantation
- Evaluation of Safety and Pharmacokinetics of Forimtamig in Patients With Relapsed or Refractory Multiple Myeloma
- A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
Data & Insights
Has run more than one trial at 235 of 384 partner sites.
Specializations
Multiple Myeloma Research
The investigator specializes in treating relapsed and refractory multiple myeloma, exploring innovative therapeutic approaches including CAR-T cell therapies and novel drug combinations.
- BCMA-directed therapies
- Combination immunotherapy regimens
- Novel agent development for resistant disease
Additional focus includes treatment strategies for newly diagnosed patients and those who have received prior therapies.
Lymphoma Treatment
Extensive work in both B-cell lymphomas and T-cell lymphomas, with particular emphasis on developing targeted therapies for various lymphoma subtypes.
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Peripheral T-Cell Lymphoma
Focus on immunotherapy approaches and novel drug combinations for both initial treatment and relapsed disease.
Cellular Therapy Development
Leading research in gene-modified T cell therapies and their applications across various hematologic malignancies.
- CAR-T cell therapy optimization
- Long-term safety monitoring
- Novel cellular therapy approaches
Particular interest in understanding and improving long-term outcomes of cellular therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.